AFMDQ (AFMDQ) Stock Price & Analysis
AFMDQ (AFMDQ) rose 0.00% to USD 0 as of June 10, 2026 at 03:14 UTC, according to Nexqual real-time market data.
AFMDQ last closed at USD 0; the session ranged USD 0–0 on volume of 2,600 shares. Market capitalization is $1,639, with a 52-week range of USD 0–0.1 (PNK). Source: Nexqual, June 10, 2026 at 03:14 UTC.
Key Statistics (as of June 10, 2026 at 03:14 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.1 |
| Volume | 2,600 shares |
| Market Cap | $1,639 |
| Exchange | PNK |
Technical Analysis (AFMDQ)
Nexqual's technical model rates AFMDQ "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 03:14 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.07 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (AFMDQ)
Wall Street analysts rate AFMDQ "None", per Nexqual as of June 10, 2026 at 03:14 UTC.
| Consensus Rating | None |
|---|
Earnings (AFMDQ)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-09-30 | USD -0.94 vs est -0.95 ▲ beat |
| 2024-06-30 | USD -1.01 vs est -1.02 ▲ beat |
| 2024-03-31 | USD -1.27 vs est -1.58 ▲ beat |
| 2023-12-31 | USD -6.52 vs est -1.61 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:14 UTC.
Financials & Fundamentals (AFMDQ)
| Total Revenue | $5.64M |
|---|---|
| Revenue Growth (YoY) | -91.60% |
| Gross Margin | +100.00% |
| Operating Margin | -8709.15% |
| Profit Margin | +0.00% |
| ROE | -149.49% |
| Debt / Equity | 74.96 |
| Current Ratio | 1.93 |
| Total Cash | $24.10M |
| Total Debt | $12.89M |
| Free Cash Flow | $-45.39M |
Source: Nexqual, June 10, 2026 at 03:14 UTC.
Financial Health Score (AFMDQ)
Nexqual rates AFMDQ's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:14 UTC.
| Growth | Critical — Revenue -80% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $24M cash vs $13M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$45M, burning cash |
| Efficiency | Critical — ROE -149%, ROA -49.4% |
Ownership (AFMDQ)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.01% |
| Shares Outstanding | 16.39M |
| Float | 15.48M |
| Short % of Float | +3.75% |
Source: Nexqual, June 10, 2026 at 03:14 UTC.
Leadership (AFMDQ)
AFMDQ is led by Wolfgang Fischer (age 61), MD, COO, Chief Strategy Officer & Member of Management Board, per Nexqual as of June 10, 2026 at 03:14 UTC.
| MD, COO, Chief Strategy Officer & Member of Management Board | Wolfgang Fischer (age 61) |
|---|---|
| Head of Investor Relations & Director of Investor Relations | Alexander Fudukidis |
| Vice President of Marketing & Communications | Mary Beth Sandin |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ADAPY | Adaptimmune Therapeutics plc | USD 0.03 | ▼ 20.59% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.72 | ▲ 5.52% |
| CALA | Calithera Biosciences, Inc. | USD 0 | ▲ 0% |
| OTIC | Otonomy, Inc. | USD 0 | ▲ 0% |
| KPTI | Karyopharm Therapeutics Inc. | USD 8.69 | ▼ 4.3% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:14 UTC. This page is informational and not investment advice.